YENDRYS CALDERIN: Open Payments
NPI 1528524980 · BRANDON, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,163 in 49 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,194 · 2025 $1,163
Food & beverage: $1,163
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $311 |
| Lilly USA, LLC | 3 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $118 |
| GENZYME CORPORATION | 3 | $96 |
| Celltrion USA Inc. | 3 | $91 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $79 |
| Gilead Sciences, Inc. | 3 | $76 |
| Janssen Biotech, Inc. | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Exact Sciences Corporation | 2 | $38 |
Products named: DUPIXENT, ZEPBOUND, SKYRIZI, VEGZELMA, RINVOQ, CREON, ENTYVIO, TREMFYA.
Industry payments across FL — which companies pay providers there.
